177 related articles for article (PubMed ID: 18641023)
1. Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis.
Gertz MA; Lacy MQ; Lust JA; Greipp PR; Witzig TE; Kyle RA
Haematologica; 2008 Sep; 93(9):1402-6. PubMed ID: 18641023
[TBL] [Abstract][Full Text] [Related]
2. Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis.
Gertz MA; Kyle RA
Arch Intern Med; 1990 Mar; 150(3):629-33. PubMed ID: 2310282
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
Comenzo RL
Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
[TBL] [Abstract][Full Text] [Related]
4. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC
Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534
[TBL] [Abstract][Full Text] [Related]
5. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone.
Bochtler T; Hegenbart U; Kunz C; Benner A; Seckinger A; Dietrich S; Granzow M; Neben K; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
Amyloid; 2014 Mar; 21(1):9-17. PubMed ID: 24455967
[TBL] [Abstract][Full Text] [Related]
6. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
Leung N; Dispenzieri A; Lacy MQ; Kumar SK; Hayman SR; Fervenza FC; Cha SS; Gertz MA
Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplasia and acute myeloid leukaemia in a case of rheumatoid arthritis with secondary amyloidosis treated with chlorambucil.
Balakrishnan C; Pathan E; Khodaiji S; Dasgupta A; Mangat G; Joshi VR
J Assoc Physicians India; 2004 May; 52():423-5. PubMed ID: 15656036
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
Lacy MQ; Dispenzieri A; Hayman SR; Kumar S; Kyle RA; Rajkumar SV; Edwards BS; Rodeheffer RJ; Frantz RP; Kushwaha SS; Clavell AL; Dearani JA; Sundt TM; Daly RC; McGregor CG; Gastineau DA; Litzow MR; Gertz MA
J Heart Lung Transplant; 2008 Aug; 27(8):823-9. PubMed ID: 18656793
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.
Gertz MA; Leung N; Lacy MQ; Dispenzieri A; Zeldenrust SR; Hayman SR; Buadi FK; Dingli D; Greipp PR; Kumar SK; Lust JA; Rajkumar SV; Russell SJ; Witzig TE
Nephrol Dial Transplant; 2009 Oct; 24(10):3132-7. PubMed ID: 19403931
[TBL] [Abstract][Full Text] [Related]
10. Localized amyloidosis: a survey of 35 French cases.
Paccalin M; Hachulla E; Cazalet C; Tricot L; Carreiro M; Rubi M; Grateau G; Roblot P
Amyloid; 2005 Dec; 12(4):239-45. PubMed ID: 16399649
[TBL] [Abstract][Full Text] [Related]
11. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis.
Palladini G; Russo P; Nuvolone M; Lavatelli F; Perfetti V; Obici L; Merlini G
Blood; 2007 Jul; 110(2):787-8. PubMed ID: 17606766
[No Abstract] [Full Text] [Related]
12. [Follicular mucinosis with generalized para-amyloidosis as a cutaneous paraneoplastic syndrome in myeloma (IgD and light chain plasmacytoma). A demonstration of the course using melphalan-prednisone therapy with a 3 years remission].
Jänner M; Lippert HD; Stolzenbach G
Z Hautkr; 1977 Aug; 52(16):873-40. PubMed ID: 408988
[No Abstract] [Full Text] [Related]
13. [A case of primary amyloidosis].
Ardashev VN; Potekhin NP; Rukavitsyn OA; Borisov AG; Malysheva SA
Klin Med (Mosk); 2006; 84(6):56-9. PubMed ID: 16875072
[TBL] [Abstract][Full Text] [Related]
14. Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival.
Prokaeva T; Spencer B; Kaut M; Ozonoff A; Doros G; Connors LH; Skinner M; Seldin DC
Arthritis Rheum; 2007 Nov; 56(11):3858-68. PubMed ID: 17968927
[TBL] [Abstract][Full Text] [Related]
15. Nodular amyloidosis: review and long-term follow-up of 16 cases.
Moon AO; Calamia KT; Walsh JS
Arch Dermatol; 2003 Sep; 139(9):1157-9. PubMed ID: 12975157
[TBL] [Abstract][Full Text] [Related]
16. Clonal light chain restricted primary intrapulmonary nodular amyloidosis.
Ross P; Magro CM
Ann Thorac Surg; 2005 Jul; 80(1):344-7. PubMed ID: 15975406
[TBL] [Abstract][Full Text] [Related]
17. [Amyloidosis in a mixed pattern. Sensitivity to colchicine and melphalan].
Frustaci A; Gentiloni N; Feoli F
Minerva Med; 1981 Apr; 72(15):957-60. PubMed ID: 6784038
[TBL] [Abstract][Full Text] [Related]
18. Primary (AL) amyloidosis in plasma cell disorders.
Müller AM; Geibel A; Neumann HP; Kühnemund A; Schmitt-Gräff A; Böhm J; Engelhardt M
Oncologist; 2006; 11(7):824-30. PubMed ID: 16880241
[TBL] [Abstract][Full Text] [Related]
19. Development of systemic lambda-light chain amyloidosis in a patient with gamma-heavy chain deposition disease during long-term follow-up.
Komatsuda A; Maki N; Wakui H; Ohtani H; Hatakeyama T; Yasuda T; Nakamoto Y; Imai H; Sawada K
Nephrol Dial Transplant; 2005 Feb; 20(2):434-7. PubMed ID: 15673693
[No Abstract] [Full Text] [Related]
20. [Primary amyloidosis associated to severe factor X deficiency].
Pérez Martínez J; Llamas F; López Montes A; Massó P; Poblet E; López Rubio E; Gallego E; Gómez Roldán C
Nefrologia; 2004; 24(5):493-8. PubMed ID: 15648909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
